Molecular Partners Raises Series A

Molecular Partners AG of Switzerland has raised CHF 18.5 million ($15.56m) in Series A funding. Index Ventures led the deal, and was joined by BB Biotech, Johnson & Johnson Development Corp. and Endeavor. The company developers repeat proteins designed to act as equivalent alternatives to antibodies, or as replacements if antibodies fail. www.molecularpartners.com